It is essential that context-appropriate health research and health interventions take place in countries with economy in transition. The aims of this study were to describe the clinical characteristics, management, and in-hospital outcomes of acute coronary syndrome (ACS) patients with heart failure (HF) in Montenegro and Serbia. The data of this study are a framework of the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC; NCT01218776), a multi-national and multicentre registry of patients hospitalized with ACS in the European countries that emerged from the Socialist era. The present analysis focused on participants admitted to 15 hospitals in
Introduction
The reduction in mortality in patients with heart failure (HF) and ST-segment elevation myocardial infarction (STEMI) has been attributed to the increased availability of primary percutaneous coronary intervention (PCI), allowing sustained recanalization of the infarct-related artery. [1] [2] [3] [4] [5] In centres without catheterization facilities, the priority should be transferring the patients to a tertiary centre where this can be performed. Transfer should be performed as soon as possible after diagnosis has been made. In the setting of STEMI, if transfer for primary PCI is expected to be delayed, thrombolysis should be initiated. 5, 6 Given the strong association between STEMI and HF, it is critical to understand the prognostic significance of HF for other acute coronary syndrome (ACS) subsets, namely unstable angina and non-STEMI (UA/NSTEMI). [7] [8] [9] Little information is available for these patients. [10] [11] [12] [13] [14] The aim of this work was to describe the clinical characteristics, and in-hospital management/outcomes of ACS patients with HF in Montenegro and Serbia enrolled in the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) during the period between October 2012 and August 2013.
Methods
Patients and data collection ISACS-TC registry is a multi-national and multicentre registry of patients hospitalized with ACS in the European countries with economy in transition. Details of the ISACS-TC (NCT01218776) registry have been previously reported. 15, 16 Patients were potentially eligible if they were admitted to the hospital with an admission diagnosis of suspected ACS. All the patients were assigned to one of the following categories: STEMI and UA/NSTEMI. Specifically, the great majority of patients were included in the study if they fulfilled a revised ESC/ACC definition of myocardial infarction 17 (raised cardiac troponin concentration above the 10% coefficient of variation taken 12-24 h after the onset of symptoms or raised creatine kinase concentration above twice the upper limit of normal) accompanied by at least one of the following: (i) ischaemic symptoms; (ii) development of pathological Q-wave on the electrocardiogram (ECG); (iii) ECG changes indicative of ischaemia; (iv) delivery of primary coronary angioplasty; and (v) compatible post-mortem findings.
Patients were excluded if they had active cancer or autoimmune inflammatory disease leavening a cohort study based on 1138 patients. After excluding 23 patients with Killip Class IV (cardiogenic shock), the total cohort study was of 1115 patients. Patients were admitted to seven hospitals in Serbia (five tertiary centres and two secondary centres) and eight hospitals in Montenegro (one tertiary centre and seven secondary centres). Demographic and medical data were collected for all patients during hospitalization.
Primary endpoints
The primary endpoints were the use of PCI and coronary artery bypass graft (CABG), thrombolysis, and cardiac medications, and in-hospital incidence of death. We also evaluated the impact of Killip Classes II and III (HF at admission) on in-hospital mortality.
Statistical analysis
The comparison of continuous variables between patients with and without HF was performed using the Student's t-test. Categorical variables were compared using Pearson's x 2 test (or Fisher's exact test for expected cells ,5). Continuous variables were described by means and standard deviations. Multivariate logistic regression analysis with a backward stepwise procedure, using 0.2 as a significance level for removal from the model, was performed to estimate adjusted odds ratios (ORs) of the potentially independent predictors of HF at admission and predictors of in-hospital mortality. For all analysis, statistical significance was defined as a value of P , 0.05. All data were analysed with the STATA 11 statistical software.
Results

Patient population
Among ACS 1115 patients, 94 (8.4%) had HF (Killip Class II or III) at hospital admission. The clinical characteristics of patients with HF at hospital admission are summarized in Table 1 . The mean age of the overall cohort was 62.4 + 11.4 years. Patients with HF were significantly older than those without HF were more likely to be hypertensive, to have a prior CABG and to present with STEMI (73.4 vs. 62.4%). They were less likely to be admitted within 12 h from symptoms onset. Serum creatinine, heart rate, and systolic blood pressure were statistically different between patients with and without HF. Table 2 summarizes medication use and in-hospital procedures of HF patients. The use of angiotensin-converting enzyme (ACE) inhibitors and unfractioned heparin was significantly higher among patients with HF compared with their counterpart without HF. Patients with HF were less likely to undergo invasive cardiac procedures and thrombolysis.
Treatment patterns
Predictors of heart failure
After applying a multivariate logistic regression with a backward selection approach, the relevant predictor of HF at admission ( 
Heart failure and adverse outcomes
In-hospital death was remarkably higher for patients with HF compared with those without HF (13.8 vs. 3.7%; OR 4.15, 95% CI 1.94-8.34, P , 0.001). After adjustment for differences in clinical characteristics, HF was still associated with higher mortality compared with the remaining cohort (OR 2.88, 95% CI 1.22-6.79, P ¼ 0.016) ( Table 4) . We performed a separate analysis for the subgroup of NSTEMI/ UA patients, and in-hospital death was still remarkably higher for patients with HF (25 vs. 3.2%; OR 10.22, 95% CI 3.44-30.35, P , 0.001). Table 5 reports that HF was a significant independent predictor of in-hospital death after adjusting for confounders (OR 5.39, 95% CI 1.19-24.53, P ¼ 0.029).
Other predictors of mortality
On multivariate logistic regression analysis (Table 4) , older age and prior PCI had significant associations with increased mortality. Coronary revascularization, betablockers, and ACE inhibitors were significantly associated with decreased mortality.
In the subgroup of UA/NSTEMI patients, older age, history of diabetes, and prior PCI were independent predictors of in-hospital mortality, whereas beta-blockers were associated with a reduction in mortality ( Table 5) . CAD, coronary artery disease; MI, acute myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; HF, heart failure; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial infarction.
Discussion
Most of the published data on HF is based on work in the industrialized world. There are few or no available data from the developing world, and especially from those European countries with the economy in transition. 18 The current study wished to draw this information in Montenegro.
The overall incidence of HF complicating ACS in our study was 8.4%. Heart failure on hospital admission was associated with an approximately 3-to 4-fold increase in hospital death rates. Of note, in-hospital mortality of HF patients was 13.8%, which is relatively high, when compared with other data reported in large US and European registries (3.8-4%). 19, 20 Heart failure was associated with longer delays in seeking care, which may have prevented patients from receiving timely diagnosis or optimal therapies. Although it is well known that HF is a frequent and severe complication of acute myocardial infarction, the current study shows that HF is a common complication of all forms of ACS. Heart failure was, indeed, associated with a 5-fold increase in mortality rates in UA/NSTEMI (OR 5.39, 95% CI 1.19-24.53, P ¼ 0.029).
Patients with HF were also significantly less likely to undergo invasive cardiac procedures and thrombolysis than those without HF. Similar findings have been reported by the CRUSADE investigators, who found that high-risk ACS patients (represented by prior CABG, prior or current HF) underwent less invasive management compared with lower risk patients. 21 Because information regarding physicians' recommendations to patients was not available in our data set, we cannot fully address this issue. These findings may have several explanations. First, physicians' perceptions regarding severity of illness and intervention risk in the HF group may be wrong. Secondly, differences in procedure use may be accounted for by an excessive use of procedures among patients without HF rather than underuse among ,0.001 ACE, angiotensin-converting enzyme; LMWH, low-molecular-weight heparin; UFH, unfractioned heparin; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; HF, heart failure. HF, heart failure; CAD, coronary artery disease; MI, acute myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; OR, odds ratio; CI, confidence interval. HF individuals. Indeed, the use of catheterization and coronary revascularization (61.9%) in our patients without HF was substantially greater than that observed by Spencer et al. 22 in a study of 606 500 US patients with myocardial infarction (39%). It should be noted, however, that the rate in our HF group (49%) was still greater than this national US norm (20%). Finally, medical economics may have played a role. The previous work has shown that resource use declines by virtue of a reduction in discretionary services when financial disincentives exist in a health-care setting. Limitations described in the Master Plan of Montenegro include weak employment control and low salaries. 23 The results of our study suggest significant underutilization of important cardiac therapies for patients with HF. ACE inhibitors have been shown to be efficacious as both an early acute and chronic therapy for patients with acute myocardial infarction. [24] [25] [26] [27] We suspect that reluctance to use ACE inhibitors in patients with HF stems from fear of treating physicians to precipitate recurrent episodes of HF or ischaemic steal syndrome during administration of vasodilators. [28] [29] [30] The reason for underutilization of other therapies is unclear. [31] [32] [33] [34] Early administration of heparins can be difficult in the most critically ill patients, but their proven efficacy mandates that they be given necessarily.
Study limitations
As with any observational study, the present findings have several limitations. Although this registry involves 15 hospitals throughout Montenegro and Serbia, participating sites may not be representative of all Montenegro and Serbia hospitals. A further limitation of this analysis is the short duration of follow-up. While the results of our study may not be generalized to the long-term outcome of patients, similarities with long-term studies are worth noting. In addition, there is no information available on patients with bad response to conventional treatment, which may have influenced prognosis. 35, 36 Finally, because of the observational nature of the study, we cannot make casual associations between therapy use and hospital outcomes.
Conclusions
In conclusion, in this cohort of patients with ACS in Montenegro and Serbia, HF complicates almost 9% of cases and is associated with a significant increase in in-hospital mortality all throughout the spectrum of ACSs. An adjusted in-hospital mortality rate was strongly associated with HF (OR 2.88, P ¼ 0.016). Heart failure was associated with older age, hypertension, prior CABG, and STEMI. There is a need to optimize the use of medications and cardiovascular interventions in these high-risk patients.
